Express Scripts Settlement Validates Stand-Alone Section 5 Enforcement—and Offers Road Map for Cooperative Resolution For respondents facing novel Federal Trade Commission theories, the lesson is that ...

A Chicago plumbers’ union is accusing Express Scripts Inc. of giving certain drugmakers preferential patient access in exchange for billions of dollars in rebates it withheld from the union health ...

Nation’s largest Pharmacy Benefits Manager accused of gaming its drug formulary and withholding billions in rebates from PBM customers. NEW YORK--(BUSINESS WIRE)--Today, Bernstein Litowitz Berger & ...

On February 4, 2026, Express Scripts agreed to a settlement with the Federal Trade Commission (FTC) in the agency’s administrative case against the nation’s three largest pharmacy benefit managers ...

The Federal Trade Commission has announced what it called a "landmark settlement" with Express Scripts over insulin pricing. The settlement resolves a lawsuit alleging that Express Scripts' conduct ...

The FTC first sued Express Scripts, CVS Caremark, and Optum in 2024, claiming anticompetitive and unfair rebating practices surrounding insulin. “Caremark, [Express Scripts], and Optum—as medication ...

FTC allegations centered on “Big 3” PBMs using anticompetitive rebating and affiliated-pharmacy channel dynamics to inflate insulin list prices and capture rebate and margin-driven revenues.

Express Scripts, a pharmacy benefit manager and subsidiary of Cigna (CI), has reached a settlement with the FTC over accusations that it artificially inflated the prices of insulin drugs, violating ...

The Federal Trade Commission said it has reached a settlement with Express Scripts, resolving an earlier lawsuit that alleged the pharmacy benefit manager artificially inflated insulin drug prices.

The Trump administration announced that the company, a pharmacy benefit manager, had agreed to make significant changes to its practices. By Rebecca Robbins and Reed Abelson The reporters have ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...